Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback